홈 › 급성 골수성 백혈병 › 코네티컷
코네티컷의 급성 골수성 백혈병 임상 시험
급성 골수성 백혈병 관련 연구 19개가 코네티컷 내 여러 지역에서 참여자를 모집하고 있습니다.
코네티컷의 도시
공식 연구 텍스트(영어)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06317649Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Hartford HealthCare Cancer Institute, Hartford
- Yale University School of Medicine, New Haven
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07007312Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT05554406A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
- Yale - New Haven Hospital / Cancer Center, New Haven
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT07751991Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Yale University, New Haven
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT06484062MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT05564390Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT05554393Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Clinical Trial Site, Farmington
피험자 모집 중3상
12세 이상 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT07211958A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Yale University, New Haven
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 6. 업데이트됨 · NCT04256317A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
피험자 모집 중3상
6 Months – 21 Years · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT04293562The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Smilow Cancer Hospital at Yale New Haven, New Haven
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 20. 업데이트됨 · NCT06001788ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- Yale University, Yale Cancer Center, New Haven
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT06656494A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Yale New Haven Hospital, New Haven
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Yale New Haven Hospital, New Haven
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 15. 업데이트됨 · NCT05768932Revumenib in Combination With 7+3 + Midostaurin in AML
- Yale Cancer Center, New Haven
피험자 모집 중1상
18세 ~ 75세 · 모든 성별 · 2026. 3. 25. 업데이트됨 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 13. 업데이트됨 · NCT05735184Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Yale University, New Haven
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 8. 26. 업데이트됨 · NCT03850574ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.